Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015 (2015), Article ID 934791, 7 pages
http://dx.doi.org/10.1155/2015/934791
Research Article

Decreased Insulin Sensitivity and Impaired Fibrinolytic Activity in Type 2 Diabetes Patients and Nondiabetics with Ischemic Stroke

1Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Dr Subotica 13, 11000 Belgrade, Serbia
2Clinic for Neurology, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Dr Subotica 6, 11000 Belgrade, Serbia
3Department for Operations Research and Statistics, Faculty of Organizational Sciences, University of Belgrade, Jove Ilica 154, 11 000 Belgrade, Serbia

Received 30 September 2014; Accepted 3 November 2014

Academic Editor: Ilias Migdalis

Copyright © 2015 Aleksandra Jotic et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. A. Defronzo, R. C. Bonadonna, and E. Ferrannini, “Pathogenesis of NIDDM: a balanced overview,” Diabetes Care, vol. 15, no. 3, pp. 318–368, 1992. View at Google Scholar · View at Scopus
  2. K. Matsumoto, S. Miyake, M. Yano et al., “Insulin resistance and classic risk factors in type 2 diabetic patients with different subtypes of ischemic stroke,” Diabetes Care, vol. 22, no. 7, pp. 1191–1195, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Urabe, H. Watada, Y. Okuma et al., “Prevalence of abnormal glucose metabolism and insulin resistance among subtypes of ischemic stroke in Japanese patients,” Stroke, vol. 40, no. 4, pp. 1289–1295, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Rundek, H. Gardener, Q. Xu et al., “Insulin resistance and risk of ischemic stroke among nondiabetic individuals from the Northern Manhattan study,” Archives of Neurology, vol. 67, no. 10, pp. 1195–1200, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. R. G. Wieberdink, P. J. Koudstaal, A. Hofman, J. C. M. Witteman, M. M. B. Breteler, and M. A. Ikram, “Insulin resistance and the risk of stroke and stroke subtypes in the nondiabetic elderly,” American Journal of Epidemiology, vol. 176, no. 8, pp. 699–707, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. H.-Y. Park, D.-S. Park, H.-S. Lee, H. Chang, Y.-S. Kim, and K.-H. Cho, “Correlation Between insulin resistance and intracranial atherosclerosis in patients with ischemic stroke without diabetes,” Journal of Stroke and Cerebrovascular Diseases, vol. 17, no. 6, pp. 401–405, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Pyörälä, H. Miettinen, M. Laakso, and K. Pyörälä, “Hyperinsulinemia and the risk of stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study,” Stroke, vol. 29, no. 9, pp. 1860–1866, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. A. R. Folsom, M. L. Rasmussen, L. E. Chambless et al., “Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke,” Diabetes Care, vol. 22, no. 7, pp. 1077–1083, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. R. E. Pratley and C. Weyer, “The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus,” Diabetologia, vol. 44, no. 8, pp. 929–945, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Vague, I. Juhan-Vague, M. F. Aillaud et al., “Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects,” Metabolism, vol. 35, no. 3, pp. 250–253, 1986. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Auwerx, R. Bouillon, D. Collen, and J. Geboers, “Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus,” Arteriosclerosis, vol. 8, no. 1, pp. 68–72, 1988. View at Publisher · View at Google Scholar · View at Scopus
  12. J.-H. Jansson, B. Johansson, K. Boman, and T. K. Nilsson, “Hypofibrinolysis in patients with hypertension and elevated cholesterol,” Journal of Internal Medicine, vol. 229, no. 4, pp. 309–316, 1991. View at Publisher · View at Google Scholar · View at Scopus
  13. D. J. Schneider and B. E. Sobel, “PAI-1 and diabetes: a journey from the bench to the bedside,” Diabetes Care, vol. 35, no. 10, pp. 1961–1967, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Festa, R. D'Agostino Jr., R. P. Tracy, and S. M. Haffner, “Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study,” Diabetes, vol. 51, no. 4, pp. 1131–1137, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. C. J. Lyon and W. A. Hsueh, “Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease,” The American Journal of Medicine, vol. 115, no. 8, pp. 62–68, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. J. B. Meigs, C. J. O'Donnell, G. H. Tofler et al., “Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study,” Diabetes, vol. 55, no. 2, pp. 530–537, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Natali, E. Toschi, S. Baldeweg et al., “Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes,” Diabetes, vol. 55, no. 4, pp. 1133–1140, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. E. L. Air and B. M. Kissela, “Diabetes, the metabolic syndrome, and ischemic stroke: epidemiology and possible mechanisms,” Diabetes Care, vol. 30, no. 12, pp. 3131–3140, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. World Health Organization, “Definition, diagnosis, and classification: diabetes mellitus: report of a WHO study group,” Tech. Rep. 727, World Health Organization, Geneva, Switzerland, 1985. View at Google Scholar
  20. “Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III,” Stroke, vol. 21, no. 4, pp. 637–676, 1990. View at Publisher · View at Google Scholar
  21. G. Pacini and R. N. Bergman, “MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test,” Computer Methods and Programs in Biomedicine, vol. 23, no. 2, pp. 113–122, 1986. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Shinozaki, H. Naritomi, T. Shimizu et al., “Role of insulin resistance associated with compensatory hyperinsulinemia in ischemic stroke,” Stroke, vol. 27, no. 1, pp. 37–43, 1996. View at Publisher · View at Google Scholar · View at Scopus
  23. Y.-Y. Wang, S.-Y. Lin, Y.-H. Chuang, C.-J. Chen, K.-C. Tung, and W. H.-H. Sheu, “Adipose proinflammatory cytokine expression through sympathetic system is associated with hyperglycemia and insulin resistance in a rat ischemic stroke model,” American Journal of Physiology—Endocrinology and Metabolism, vol. 300, no. 1, pp. E155–E163, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. Y.-Y. Wang, C.-J. Chen, S.-Y. Lin, Y.-H. Chuang, W. H.-H. Sheu, and K.-C. Tung, “Hyperglycemia is associated with enhanced gluconeogenesis in a rat model of permanent cerebral ischemia,” Molecular and Cellular Endocrinology, vol. 367, no. 1-2, pp. 50–56, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. Y.-Y. Wang, S.-Y. Lin, Y.-H. Chuang, W. H.-H. Sheu, K.-C. Tung, and C.-J. Chen, “Activation of hepatic inflammatory pathways by catecholamines is associated with hepatic insulin resistance in male ischemic stroke rats,” Endocrinology, vol. 155, no. 4, pp. 1235–1246, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. A. I. Calleja, E. Cortijo, P. García-Bermejo et al., “Blood biomarkers of insulin resistance in acute stroke patients treated with intravenous thrombolysis: temporal profile and prognostic value,” Journal of Diabetes Research & Clinical Metabolism, vol. 2, article 2, 2013. View at Publisher · View at Google Scholar
  27. M. F. Saad, R. L. Anderson, A. Laws et al., “A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance,” Diabetes, vol. 43, no. 9, pp. 1114–1121, 1994. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Howard, R. Bergman, L. E. Wagenknecht et al., “Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the ‘minimal model’,” Annals of Epidemiology, vol. 8, no. 6, pp. 358–369, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. A. R. Folsom, M. L. Rasmussen, L. E. Chambless et al., “Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke,” Diabetes Care, vol. 22, no. 7, pp. 1077–1083, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Kuusisto, L. Mykkänen, K. Pyörälä, and M. Laakso, “Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects,” Stroke, vol. 25, no. 6, pp. 1157–1164, 1994. View at Publisher · View at Google Scholar · View at Scopus
  31. E. López-Cancio, A. Galán, L. Dorado et al., “Biological signatures of asymptomatic extra- and intracranial atherosclerosis: the Barcelona-AsIA (Asymptomatic Intracranial Atherosclerosis) Study,” Stroke, vol. 43, pp. 2712–2719, 2012. View at Publisher · View at Google Scholar
  32. X. Liang, T. Kanjanabuch, S.-L. Mao et al., “Plasminogen activator inhibitor-1 modulates adipocyte differentiation,” The American Journal of Physiology: Endocrinology and Metabolism, vol. 290, no. 1, pp. E103–E113, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Iacoviello, C. Agnoli, A. de Curtis et al., “Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: the EPICOR study,” British Medical Journal, vol. 3, no. 11, article 12, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. M. W. Mansfield, A. J. Catto, A. M. Carter, and P. J. Grant, “Fibrinolytic measurements in type 2 diabetic patients with acute cerebral infarction,” Diabetic Medicine, vol. 15, no. 11, pp. 953–957, 1998. View at Publisher · View at Google Scholar
  35. L. Johansson, J.-H. Jansson, K. Boman, T. K. Nilsson, B. Stegmayr, and G. Hallmans, “Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke,” Stroke, vol. 31, no. 1, pp. 26–32, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Kain, A. J. Catto, J. Young, J. Bamford, J. Bavington, and P. J. Grant, “Insulin resistance and elevated levels of tissue plasminogen activator in first-degree relatives of South Asian patients with ischemic cerebrovascular disease,” Stroke, vol. 32, no. 5, pp. 1069–1073, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Mavri, M.-C. Alessi, and I. Juhan-Vague, “Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases,” Journal of Internal Medicine, vol. 255, no. 4, pp. 448–456, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Kristensen, J. Malm, T. K. Nilsson, J. Hultdin, B. Carlberg, and T. Olsson, “Increased fibrinogen levels and acquired hypofibrinolysis in young adults with ischemic stroke,” Stroke, vol. 29, no. 11, pp. 2261–2267, 1998. View at Publisher · View at Google Scholar · View at Scopus
  39. P.-G. Wiklund, L. Nilsson, S. N. Ardnor et al., “Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts,” Stroke, vol. 36, no. 8, pp. 1661–1665, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. J. B. Mcgill, D. J. Schneider, C. L. Arfken, C. L. Lucore, and B. E. Sobel, “Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients,” Diabetes, vol. 43, no. 1, pp. 104–109, 1994. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Lindgren, C. Lindoff, B. Norrving, B. Åstedt, and B. B. Johansson, “Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients,” Stroke, vol. 27, no. 6, pp. 1066–1071, 1996. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Mykkanen, T. Ronnemaa, J. Marniemi, S. M. Haffner, R. Bergman, and M. Laakso, “Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 14, no. 8, pp. 1264–1271, 1994. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Rydzewski, K. Sakata, A. Kobayashi et al., “Changes in plasminogen activator inhibitor 1 and tissue-type plasminogen activator during exercise in patients with coronary artery disease,” Haemostasis, vol. 20, no. 5, pp. 305–312, 1990. View at Google Scholar · View at Scopus
  44. A. Panahloo, V. Mohamed-Ali, A. Lane, F. Green, S. E. Humphries, and J. S. Yudkin, “Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene,” Diabetes, vol. 44, no. 1, pp. 37–42, 1995. View at Publisher · View at Google Scholar · View at Scopus
  45. J. F. Arenillas, J. Alvarez-Sabín, C. A. Molina et al., “C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease,” Stroke, vol. 3, pp. 2463–2470, 2003. View at Google Scholar
  46. A. Tjärnlund-Wolf, H. Brogren, E. H. Lo, and X. Wang, “Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases,” Stroke, vol. 43, no. 10, pp. 2833–2839, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. A. H. Kissebah, S. Alfarsi, D. J. Evans, and P. W. Adams, “Plasma low density lipoprotein transport kinetics in noninsulin-dependent diabetes mellitus,” Journal of Clinical Investigation, vol. 71, no. 3, pp. 655–667, 1983. View at Publisher · View at Google Scholar · View at Scopus
  48. M. C. Alessi, F. Peiretti, P. Morange, M. Henry, G. Nalbone, and I. Juhan-Vague, “Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease,” Diabetes, vol. 46, no. 5, pp. 860–867, 1997. View at Publisher · View at Google Scholar · View at Scopus